SEHK:9995Biotechs
The Bull Case For RemeGen (SEHK:9995) Could Change Following AbbVie’s RC148 Licensing Deal - Learn Why
On 12 January 2026, AbbVie and RemeGen announced an exclusive licensing agreement for RC148, a PD-1/VEGF-targeted bispecific antibody, giving AbbVie rights outside Greater China in exchange for a US$650 million upfront payment plus very large potential milestone payments and tiered, double-digit royalties.
This deal not only validates RemeGen’s immuno-oncology platform, but also ties its future RC148 opportunity to AbbVie’s global ADC and solid tumor portfolio.
We’ll now examine how this...